300119 Stock Overview
Tianjin Ringpu Bio-Technology Co.,Ltd. engages in the research and development, production, and sale of veterinary raw materials, drug preparation, functional additives, and veterinary biological products.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
Tianjin Ringpu Bio-Technology Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥15.95 |
| 52 Week High | CN¥22.88 |
| 52 Week Low | CN¥11.55 |
| Beta | 0.78 |
| 1 Month Change | 9.47% |
| 3 Month Change | 13.04% |
| 1 Year Change | -27.37% |
| 3 Year Change | -43.08% |
| 5 Year Change | -12.12% |
| Change since IPO | 4.71% |
Recent News & Updates
Impressive Earnings May Not Tell The Whole Story For Tianjin Ringpu Bio-TechnologyLtd (SZSE:300119)
Apr 05
Tianjin Ringpu Bio-Technology Co.,Ltd.'s (SZSE:300119) Subdued P/E Might Signal An Opportunity
Mar 28Shareholder Returns
| 300119 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 1.0% | -1.1% | -0.4% |
| 1Y | -27.4% | -15.9% | -16.2% |
Return vs Industry: 300119 underperformed the CN Pharmaceuticals industry which returned -15.9% over the past year.
Return vs Market: 300119 underperformed the CN Market which returned -16.2% over the past year.
Price Volatility
| 300119 volatility | |
|---|---|
| 300119 Average Weekly Movement | 6.9% |
| Pharmaceuticals Industry Average Movement | 7.9% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.4% |
Stable Share Price: 300119 has not had significant price volatility in the past 3 months.
Volatility Over Time: 300119's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 2,496 | Lei Xu | www.ringpu.com |
Tianjin Ringpu Bio-Technology Co.,Ltd. engages in the research and development, production, and sale of veterinary raw materials, drug preparation, functional additives, and veterinary biological products. The company provides vaccines and drugs for poultry, waterfowl, livestock, and other animals; pet products comprising insect repellent series, ear products, nutritional supplements, anesthesia for surgery, anti-infective, antiviral, benazepril hydrochloride chewable tablets, meloxicam tablets, benzyl trimethylammonium chloride solution, etc.; and waterfowl products, including duck tempusu live/inactivated vaccine, gosling plague refined egg yolk antibody, duck infectious serositis inactivated vaccine, duck viral hepatitis refined egg yolk antibody, duck plague live vaccine, swine fever vaccine, etc. It offers ruminant products comprising cefquinome sulfate breast injection, ceftiofur hydrochloride injection, foot bath, nitrofenac injection, etc.; livestock products comprising ceftiofur injection, florfenicol powder, compound amoxicillin powder, tyvalin tartrate premix, carbasalate calcium soluble powder, florfenicol injection, etc.; and APIs comprising tilmicosin, tilmicosin phosphate, totrazuli, florfenicol, warnemulin hydrochloride, etc. In addition, the company provides potassium persulfate complex powder, concentrated glutaraldehyde solution, decyl ammonium bromide solution, and glutaraldehyde decyl ammonium bromide solution.
Tianjin Ringpu Bio-Technology Co.,Ltd. Fundamentals Summary
| 300119 fundamental statistics | |
|---|---|
| Market cap | CN¥7.38b |
| Earnings (TTM) | CN¥452.94m |
| Revenue (TTM) | CN¥2.25b |
16.3x
P/E Ratio3.3x
P/S RatioIs 300119 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300119 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.25b |
| Cost of Revenue | CN¥1.13b |
| Gross Profit | CN¥1.12b |
| Other Expenses | CN¥664.61m |
| Earnings | CN¥452.94m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 26, 2024
| Earnings per share (EPS) | 0.98 |
| Gross Margin | 49.69% |
| Net Profit Margin | 20.14% |
| Debt/Equity Ratio | 17.8% |
How did 300119 perform over the long term?
See historical performance and comparison